Evotec SE

20-F13D13G

Schedule 13D - Activist Investments

NASDAQ
EVO
Evotec SE
SCHEDULE: MAK Capital Secures Board Seat at Evotec SE
MAK Capital Fund LP has entered into a cooperation agreement with Evotec SE, resulting in the nomination of Dr. Wolfgang Hofmann to the company's Supervisory Board.
NASDAQ
EVO
Evotec SE
SCHEDULE: MAK Capital Urges Evotec to Spin Off Just Biologics
Activist investor MAK Capital, holding a 7% stake in Evotec SE, is pushing for a U.S. IPO of Just Biologics and accelerated restructuring to unlock shareholder value.
Worse than expected
Delay expected
Capital raise
NASDAQ
EVO
Evotec SE
SCHEDULE: Activist Investor MAK Capital Takes 7% Stake in Evotec SE
MAK Capital has acquired a 7.0% stake in Evotec SE and is pushing for strategic and governance improvements, including a board nomination and a spin-out of Just-Evotec Biologics.
NASDAQ
EVO
Evotec SE
SCHEDULE: Triton Funds Convert Evotec SE Swap to Direct Equity
Triton-affiliated entities, including Excalibur LuxCo SARL, have converted a swap agreement into direct ownership of 3.55 million Evotec SE ordinary shares, maintaining a 9.99% stake.

Schedule 13G - Passive Investments

NASDAQ
EVO
Evotec SE
SCHEDULE: MAK Capital Discloses 5.3% Stake in Evotec SE
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 5.3% beneficial ownership stake in Evotec SE, totaling 9,386,434 ordinary shares.
NASDAQ
EVO
Evotec SE
SCHEDULE: Novo Holdings Discloses 5.3% Stake in Evotec SE
Novo Holdings A/S, an investment firm, has disclosed a 5.3% beneficial ownership stake in Evotec SE, holding 9,407,883 ordinary shares.